$PM

What Are Wall Street Analysts' Target Price for Philip Morris International Stock?

Needham analyst Gerald Pascarelli maintained a Buy rating on Philip Morris International and raised his price target to $215 from $200 on July 23. The article cites a mean target of $207.43, about a 10.7% premium to the current share price, and a Street-high target of $225, implying 20.1% upside.

Original reporting
Published Aug 5, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Are Wall Street Analysts' Target Price for Philip Morris International Stock? — source image
Decision brief

The 30-second read

$PMBullishLow
01

Why it matters

A raised target can influence short-term sentiment and options positioning, but it is secondary to company-reported fundamentals.

02

Market read

Traders may use the target change as a sentiment input, but it is unlikely to drive a durable repricing without new fundamentals.

03

What to watch

The article does not include the analyst’s thesis, valuation assumptions, or any new company-specific datapoint beyond the target revision.

Relevance 4/10Novelty 4/10Timing: after-hours/next-session positioning based on analyst target change

Background

The piece summarizes Wall Street target prices and notes a recent target increase by Needham.

Company-level read

Ticker impact

$PMBullishMedium confidence
Context

Needham maintained a Buy on Philip Morris International and raised its price target to $215 from $200, implying upside versus the current share price.

Expected impact

Near-term bias to the upside, with limited follow-through unless additional fundamental news emerges.

Evidence & confidence

The article discloses a specific analyst action (rating and target change) and quantifies implied upside, but provides no new company financials, operational updates, or regulatory developments.

Market effects

Incremental sentiment support for tobacco equities, but no sector-wide policy or demand data is provided.

No specific regional catalyst beyond US analyst coverage.

No global regulatory or litigation developments mentioned.

Counterpoint

Price targets can lag fundamentals; without new earnings or guidance, the market may already price in the analyst’s view.

Key entities

  • Philip Morris International

    Subject of the article; Needham raised its price target to $215 from $200 while maintaining a Buy rating.

Related articles

$PMMed

Denver sues tobacco companies to pay for cigarette butt litter

Denver sued nine tobacco manufacturers and one distributor in state court, seeking compensation for cleanup and “continuing harms” from cigarette butt litter, citing non-biodegradable filters. The complaint names Philip Morris USA, Altria, R.J. Reynolds, Reynolds American, British American Tobacco and others, alleging littering is a foreseeable consequence of product design and marketing.

$PMMed

Philip Morris (PM) Bets $1.2B on ZYN as BAT (BTI) Steps Up Its Pouch Push

Philip Morris International (PM) opened a $1.2B, 780,000 sq ft Aurora, Colorado campus to produce ZYN nicotine pouches, after about 19 months. The FDA authorized 20 ZYN products as modified risk tobacco products on June 30. Reuters also cited PM beating Q2 estimates. The article notes Aurora cost rose from $600M and highlights BAT (BTI) growth and planned Velo Max rollout.

$PMMedAI 8/10

As FDA approves new marketing for nicotine pouches, some doctors sound alarms

The U.S. FDA authorized marketing of four new flavored nicotine pouch products from brand “on!” and raised the total recently approved to 30. The FDA also previously cleared ZYN for 20 products with a “Modified Risk Tobacco Product” claim. Philip Morris makes ZYN and Altria makes “on!”. Health groups cite youth use and addiction risks; FDA says MRTP status does not mean risk-free.

$AAPLMed

Why Did AAPL, KO, PM Stocks Jump To 52-Week Highs Today?

Apple (AAPL) shares hit $342.89 intraday and briefly topped $5T market cap after catalysts including an AI home hub and Apple Upgrade leasing program. Coca-Cola (KO) rose to $90.22 after Q2 beat, with revenue $13.37B and adj. EPS $1.03, plus higher 2026 targets. Philip Morris (PM) reached $207.76 after opening an Aurora, Colorado campus.

$PMMed

Philip Morris expands Colorado Zyn investment to $1.2 billion

Philip Morris International (PM) will invest $1.2 billion in its Aurora, Colorado facility to expand U.S. nicotine pouch production by 2028, doubling its prior $600 million pledge from 2024. The company says Zyn demand and competition in smoke-free nicotine products are driving the ramp-up, including higher-volume Zyn Ultra production.

$PMMed

New ZYN plant in Aurora goes from concept to full production in two years

Philip Morris International’s U.S. unit opened a 780,000-square-foot ZYN manufacturing facility in Aurora, Colorado, after a test-market launch there in 2014. The plant will employ about 500 workers and initially targeted a $600 million investment, now planned to reach $1.2 billion through 2028. PMI says ZYN has FDA authorization and a Modified Risk Tobacco Product designation.